^
BIOMARKER:

KRAS wild-type

i
Other names: KRAS, KRAS proto-oncogene GTPase, KRAS1, KRAS2, NS, NS3, OES, CFC2, RALD, K-Ras, RASK2, KI-RAS, C-K-RAS, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras 2, C-K-RAS, c-Ki-ras, c-Ki-ras2, Kirsten rat sarcoma viral oncogene homolog
Entrez ID:
Related biomarkers:
KRAS wild-type
Ovarian Cancer
VS-6766 + VS-6063
Sensitive: B - Late Trials
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: B - Late Trials
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: B - Late Trials
KRAS wild-type
CRC
cetuximab + palbociclib
Sensitive: C2 – Inclusion Criteria
KRAS wild-type
CRC
cetuximab
Sensitive: C2 – Inclusion Criteria
KRAS wild-type
CRC
bevacizumab
Sensitive: C2 – Inclusion Criteria
KRAS wild-type
Biliary Tract Cancer
panitumumab
Sensitive: C2 – Inclusion Criteria
KRAS wild-type
CRC
cetuximab
Resistant: C3 – Early Trials
KRAS wild-type
CRC
panitumumab + cabozantinib tablet
Sensitive: C3 – Early Trials
KRAS wild-type
CRC
SIRB
Sensitive: C3 – Early Trials
KRAS wild-type
CRC
MM-121
Sensitive: D – Preclinical